GLP-1 receptor agonists and thyroid cancer: a narrative review

CONCLUSIONS: Evidence from randomized controlled trials indicates occurrence of thyroid cancer is infrequent in individuals exposed to GLP-1 RA. Observational studies at higher risk of bias yield inconsistent results. Overall there is no conclusive evidence of elevated thyroid cancer risk. These findings can help clinicians when addressing patient's concerns about a potential yet unproven link between GLP-1 RA therapy and thyroid cancer. .PMID:38343381 | DOI:10.1089/thy.2023.0530
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Authors: Source Type: research